Original language | English (US) |
---|---|
Pages (from-to) | 2316-2319 |
Number of pages | 4 |
Journal | Molecular Therapy |
Volume | 28 |
Issue number | 11 |
DOIs | |
State | Published - Nov 4 2020 |
Externally published | Yes |
Keywords
- In utero stem cell transplantation
- adverse event
- clinical trial
- fetal
- fetal therapy
- maternal
- safety
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Pharmacology
- Drug Discovery
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials : iFeTiS Consensus Statement. / Sagar, Rachel; Almeida-Porada, Graça; Blakemore, Karin; Chan, Jerry K.Y.; Choolani, Mahesh; Götherström, Cecilia; Jaulent, Agnes; MacKenzie, Tippi C.; Mattar, Citra; Porada, Christopher D.; Peranteau, William H.; Schneider, Holm; Shaw, Steven W.; Waddington, Simon N.; Westgren, Magnus; David, Anna L.
In: Molecular Therapy, Vol. 28, No. 11, 04.11.2020, p. 2316-2319.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials
T2 - iFeTiS Consensus Statement
AU - Sagar, Rachel
AU - Almeida-Porada, Graça
AU - Blakemore, Karin
AU - Chan, Jerry K.Y.
AU - Choolani, Mahesh
AU - Götherström, Cecilia
AU - Jaulent, Agnes
AU - MacKenzie, Tippi C.
AU - Mattar, Citra
AU - Porada, Christopher D.
AU - Peranteau, William H.
AU - Schneider, Holm
AU - Shaw, Steven W.
AU - Waddington, Simon N.
AU - Westgren, Magnus
AU - David, Anna L.
N1 - Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 681045 , the German Research Foundation (DFG; grant SCHN 569/4-1 to H.S.), and the German Federal Ministry of Education and Research (BMBF; grant 01KG2008 to H.S.). A.L.D. is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre . S.N.W. received funding from MRC grants MR/R015325/1 , MR/N026101/1 , and MR/N026101/1 and NC3Rs grant NC/L001780/1 . G.A.P. and C.P. are supported by NHLBI grants HL130856 , HL135853 , and HL148681 . W.P. is supported by National Institutes of Health grants DP2HL152427 and 1R01DK123049-01 . C.G. and M.W. are supported by the Swedish Research Council ( 921-2014-7209 ). C.M. is funded by Singapore National Medical Research Council grant NMRC/CSA-INV/0012/2016 . S.W.S. is supported by Chang Gung Memorial Hospital CPRPG1J0021 . T.C.M. is supported by the California Institute for Regeneration Medicine . J.K.Y.C. is supported by Singapore Ministry of Health’s National Medical Research Council ( CSA-SI/008.2016 , CIRG/1484/2018 , and CIRG/1459/2016 ). H.S. is supported by the National Foundation for Ectodermal Dysplasias (NFED) and the German-Swiss-Austrian Ectodermal Dysplasia Patient Organization ; he also received research funding related to this project from Edimer Pharmaceuticals and the EspeRare Foundation . A.J., via the EspeRare foundation , has received philanthropic funding from the Dioraphte Foundation , Fondation Pictet , a Private Geneva Foundation , and a private donation. Funding Information: This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 681045, the German Research Foundation (DFG; grant SCHN 569/4-1 to H.S.), and the German Federal Ministry of Education and Research (BMBF; grant 01KG2008 to H.S.). A.L.D. is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. S.N.W. received funding from MRC grants MR/R015325/1, MR/N026101/1, and MR/N026101/1 and NC3Rs grant NC/L001780/1. G.A.P. and C.P. are supported by NHLBI grants HL130856, HL135853, and HL148681. W.P. is supported by National Institutes of Health grants DP2HL152427 and 1R01DK123049-01. C.G. and M.W. are supported by the Swedish Research Council (921-2014-7209). C.M. is funded by Singapore National Medical Research Council grant NMRC/CSA-INV/0012/2016. S.W.S. is supported by Chang Gung Memorial Hospital CPRPG1J0021. T.C.M. is supported by the California Institute for Regeneration Medicine. J.K.Y.C. is supported by Singapore Ministry of Health's National Medical Research Council (CSA-SI/008.2016, CIRG/1484/2018, and CIRG/1459/2016). H.S. is supported by the National Foundation for Ectodermal Dysplasias (NFED) and the German-Swiss-Austrian Ectodermal Dysplasia Patient Organization; he also received research funding related to this project from Edimer Pharmaceuticals and the EspeRare Foundation. A.J. via the EspeRare foundation, has received philanthropic funding from the Dioraphte Foundation, Fondation Pictet, a Private Geneva Foundation, and a private donation.
PY - 2020/11/4
Y1 - 2020/11/4
KW - In utero stem cell transplantation
KW - adverse event
KW - clinical trial
KW - fetal
KW - fetal therapy
KW - maternal
KW - safety
UR - http://www.scopus.com/inward/record.url?scp=85094587724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094587724&partnerID=8YFLogxK
U2 - 10.1016/j.ymthe.2020.10.012
DO - 10.1016/j.ymthe.2020.10.012
M3 - Review article
C2 - 33069884
AN - SCOPUS:85094587724
VL - 28
SP - 2316
EP - 2319
JO - Molecular Therapy
JF - Molecular Therapy
SN - 1525-0016
IS - 11
ER -